Targeted neuromodulation Micro-sized, percutaneous neuromodulation devices that offer same-day therapy in a lunchtime procedure position Ministim Corp as a disruptive, non-surgical option in pain management and neuromodulation markets. Leverage this to approach hospitals and clinics seeking minimally invasive solutions with faster patient turnover.

Boutique scale advantages With a small team and lean operations, Ministim can be highly nimble in enterprise outreach, pilot programs, and early-adopter collaborations. Emphasize fast implementation timelines, flexible service models, and personalized account management to differentiate from larger competitors.

Clinical adoption potential Active the same day and percutaneous delivery suggest strong appeal for ambulatory surgery centers and outpatient facilities. Sales efforts should target centers focusing on minimally invasive procedures, rapid patient throughput, and reduced hospitalization costs.

Strategic partnership fit In a market dominated by large players (Olympus, Medtronic, Stryker, Boston Scientific), Ministim can pursue partnerships or distribution agreements with mid-tier manufacturers or regional distributors to accelerate market access, leverage existing sales networks, and co-develop bundled solutions.

Digital signal strength Existing tech stack and web presence (AWS, Microsoft 365, Google services) enable scalable remote demonstrations, digital trials, and data-driven outreach. Leverage virtual product demos, telehealth-enabled training, and online pilot program enrollment to drive early engagement and reduce sales cycle friction.